Article

Curtis Triplitt, PharmD, on Patient-Centered Diabetes Care

In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach.

In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach. This means that therapies should be based on an individual, not a population. Patient-centered approaches require payer and provider to examine a patient’s specific characteristics and needs such as race, gender, comorbidities, and motivation. “You take those different characteristics of a patient, apply them to a particular drug, and see if they fit,” said Dr Triplitt. He compared prescribing a DPP-4 inhibitor, a well- tolerated once-a day-oral medication that fits well in a large population, with pramlintide, used in combination with insulin and in a smaller population.

Related Videos
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Lynae Darbes, PhD
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo